Symmetry Investments LP reduced its position in HCA Healthcare, Inc. (NYSE:HCA – Get Rating) by 57.1% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 6,000 shares of the company’s stock after selling 8,000 shares during the quarter. Symmetry Investments LP’s holdings in HCA Healthcare were worth $1,542,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Equitec Proprietary Markets LLC purchased a new position in HCA Healthcare in the fourth quarter worth $26,000. Amplius Wealth Advisors LLC acquired a new stake in shares of HCA Healthcare during the fourth quarter worth $27,000. PYA Waltman Capital LLC acquired a new stake in shares of HCA Healthcare during the fourth quarter worth $31,000. Ellevest Inc. lifted its position in HCA Healthcare by 1,172.7% during the fourth quarter. Ellevest Inc. now owns 140 shares of the company’s stock valued at $36,000 after purchasing an additional 129 shares during the period. Finally, D Orazio & Associates Inc. acquired a new position in HCA Healthcare during the third quarter valued at $39,000. 67.87% of the stock is currently owned by institutional investors and hedge funds.
A number of research firms have recently commented on HCA. Credit Suisse Group cut their target price on shares of HCA Healthcare from $296.00 to $260.00 and set an “outperform” rating for the company in a research note on Monday, April 25th. Wells Fargo & Company cut their target price on shares of HCA Healthcare from $267.00 to $227.00 and set an “equal weight” rating for the company in a research note on Monday, April 25th. Raymond James cut their target price on shares of HCA Healthcare from $275.00 to $245.00 and set an “outperform” rating for the company in a research note on Tuesday, April 26th. TheStreet raised shares of HCA Healthcare from a “c+” rating to a “b-” rating in a research note on Monday, March 21st. Finally, Royal Bank of Canada dropped their price objective on shares of HCA Healthcare from $291.00 to $267.00 and set an “outperform” rating for the company in a research note on Monday, April 25th. Six analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $261.38.
HCA Healthcare (NYSE:HCA – Get Rating) last issued its quarterly earnings data on Friday, April 22nd. The company reported $4.12 EPS for the quarter, missing the consensus estimate of $4.25 by ($0.13). The company had revenue of $14.95 billion during the quarter, compared to analyst estimates of $14.72 billion. HCA Healthcare had a return on equity of 405.72% and a net margin of 11.40%. The business’s revenue was up 6.9% compared to the same quarter last year. During the same quarter in the prior year, the company posted $4.14 earnings per share. As a group, research analysts predict that HCA Healthcare, Inc. will post 17.15 EPS for the current fiscal year.
The firm also recently announced a quarterly dividend, which will be paid on Thursday, June 30th. Shareholders of record on Thursday, June 16th will be issued a dividend of $0.56 per share. The ex-dividend date of this dividend is Wednesday, June 15th. This represents a $2.24 dividend on an annualized basis and a yield of 1.04%. HCA Healthcare’s dividend payout ratio (DPR) is presently 10.54%.
HCA Healthcare declared that its board has approved a share buyback plan on Thursday, January 27th that authorizes the company to repurchase $8.00 billion in outstanding shares. This repurchase authorization authorizes the company to purchase up to 10.9% of its shares through open market purchases. Shares repurchase plans are generally a sign that the company’s board of directors believes its stock is undervalued.
In other HCA Healthcare news, SVP Kathleen M. Whalen sold 500 shares of the stock in a transaction that occurred on Tuesday, May 3rd. The shares were sold at an average price of $215.38, for a total value of $107,690.00. Following the sale, the senior vice president now directly owns 11,373 shares of the company’s stock, valued at approximately $2,449,516.74. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, major shareholder Thomas F. Frist, Jr. acquired 89,100 shares of the company’s stock in a transaction on Monday, May 2nd. The stock was purchased at an average cost of $211.93 per share, for a total transaction of $18,882,963.00. Following the completion of the transaction, the insider now owns 478,955 shares in the company, valued at approximately $101,504,933.15. The disclosure for this purchase can be found here. Over the last quarter, insiders have acquired 91,370 shares of company stock worth $19,373,375 and have sold 32,655 shares worth $8,241,766. 1.50% of the stock is owned by corporate insiders.
HCA Healthcare Company Profile (Get Rating)
HCA Healthcare, Inc, through its subsidiaries, provides health care services company in the United States. The company operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy.
- Get a free copy of the StockNews.com research report on HCA Healthcare (HCA)
- The Three Most Upgraded Stocks You Can Buy Now
- MarketBeat: Week in Review 5/9 – 5/13
- Is Electronic Arts (NASDAQ: EA) Suddenly A Safe Haven?
- Beyond Meat Stock Value is Improving
- The Travel Sector Is Getting Upgraded
Receive News & Ratings for HCA Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HCA Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.